CCDC80

Summary

CCDC80 (coiled-coil domain containing 80, HGNC:30649) is a protein-coding gene on chromosome 3q13.2, encoding Coiled-coil domain-containing protein 80 (Q76M96). Promotes cell adhesion and matrix assembly.

Predicted to enable fibronectin binding activity and heparin binding activity. Predicted to be involved in extracellular matrix organization and positive regulation of cell-substrate adhesion. Predicted to act upstream of or within response to bacterium. Predicted to be located in extracellular region; interstitial matrix; and membrane. Predicted to be active in basement membrane.

Source: NCBI Gene 151887 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 150 total
• MANE Select transcript: NM_199511

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30649
Approved symbol	CCDC80
Name	coiled-coil domain containing 80
Location	3q13.2
Locus type	gene with protein product
Status	Approved
Aliases	URB, SSG1, DRO1, CL2, TCONS_00006930
Ensembl gene	ENSG00000091986
Ensembl biotype	protein_coding
OMIM	608298
Entrez	151887

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 7 protein_coding, 4 protein_coding_CDS_not_defined

ENST00000206423, ENST00000439685, ENST00000461431, ENST00000469554, ENST00000473959, ENST00000475181, ENST00000479368, ENST00000480275, ENST00000880155, ENST00000962650, ENST00000962651

RefSeq mRNA: 2 — MANE Select: NM_199511 NM_199511, NM_199512

CCDS: CCDS2968

Canonical transcript exons

ENST00000206423 — 8 exons

Exon	Start	End
ENSE00000967575	112616710	112616858
ENSE00000967576	112609978	112610081
ENSE00000967577	112607176	112607256
ENSE00001076481	112618968	112619104
ENSE00001076482	112630113	112630269
ENSE00001200029	112638028	112639916
ENSE00001358983	112640327	112641143
ENSE00003703733	112596797	112605763

Expression profiles

Bgee: expression breadth ubiquitous, 251 present calls, max score 99.75.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 169.7153 / max 8088.8722, expressed in 1411 samples.

FANTOM5 promoters (21 alternative TSS)

Promoter ID	TPM avg	Samples expressed
43814	97.8146	1103
43812	37.4259	1089
43813	17.1909	1068
43815	6.4361	1207
43797	1.8808	688
43805	1.6534	367
43798	1.6302	583
43794	0.8668	291
43803	0.8559	379
43795	0.8200	265

Top tissues by expression

264 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
parietal pleura	UBERON:0002400	99.75	gold quality
tendon of biceps brachii	UBERON:0008188	99.58	gold quality
smooth muscle tissue	UBERON:0001135	99.51	gold quality
upper arm skin	UBERON:0004263	99.36	gold quality
skin of hip	UBERON:0001554	99.34	gold quality
gall bladder	UBERON:0002110	99.34	gold quality
vena cava	UBERON:0004087	98.99	gold quality
saphenous vein	UBERON:0007318	98.56	gold quality
stromal cell of endometrium	CL:0002255	98.50	gold quality
tibia	UBERON:0000979	98.49	gold quality
upper leg skin	UBERON:0004262	98.49	gold quality
cardiac muscle of right atrium	UBERON:0003379	98.45	gold quality
peritoneum	UBERON:0002358	98.36	gold quality
omental fat pad	UBERON:0010414	98.35	gold quality
adipose tissue of abdominal region	UBERON:0007808	98.33	gold quality
body of uterus	UBERON:0009853	98.31	gold quality
colonic epithelium	UBERON:0000397	98.24	gold quality
vermiform appendix	UBERON:0001154	98.21	gold quality
right coronary artery	UBERON:0001625	98.18	gold quality
myometrium	UBERON:0001296	98.13	gold quality
descending thoracic aorta	UBERON:0002345	98.09	gold quality
pericardium	UBERON:0002407	98.04	gold quality
apex of heart	UBERON:0002098	98.03	gold quality
caecum	UBERON:0001153	97.98	gold quality
calcaneal tendon	UBERON:0003701	97.88	gold quality
tendon	UBERON:0000043	97.87	gold quality
endocervix	UBERON:0000458	97.84	gold quality
adipose tissue	UBERON:0001013	97.84	gold quality
visceral pleura	UBERON:0002401	97.64	gold quality
coronary artery	UBERON:0001621	97.62	gold quality

Single-cell (SCXA)

Detected in 23 experiment(s), a significant marker in 21.

Experiment	Marker?	Max mean expression
E-MTAB-8322	yes	2712.52
E-HCAD-15	yes	2693.90
E-MTAB-8530	yes	2479.31
E-CURD-126	yes	2323.50
E-HCAD-36	yes	2197.76
E-MTAB-8142	yes	2159.75
E-MTAB-8410	yes	1996.41
E-HCAD-11	yes	1140.59
E-MTAB-10662	yes	567.05
E-MTAB-10137	yes	540.80
E-MTAB-8205	yes	310.09
E-HCAD-1	yes	90.98
E-GEOD-135922	yes	47.17
E-HCAD-10	yes	35.84
E-MTAB-10287	yes	31.68

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): NCOA3

miRNA regulators (miRDB)

70 targeting CCDC80, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-6798-5P	100.00	65.77	699
HSA-MIR-30A-5P	100.00	76.31	3233
HSA-MIR-30B-5P	100.00	76.29	3248
HSA-MIR-30C-5P	100.00	76.29	3248
HSA-MIR-30D-5P	100.00	76.32	3233
HSA-MIR-30E-5P	100.00	76.32	3242
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-129-5P	99.88	70.26	3273
HSA-MIR-30A-3P	99.87	69.74	2928
HSA-MIR-30D-3P	99.87	69.92	2917
HSA-MIR-30E-3P	99.87	69.68	2942
HSA-MIR-6844	99.82	70.69	2423
HSA-MIR-205-5P	99.81	70.05	1557
HSA-MIR-374C-5P	99.80	72.06	2910
HSA-MIR-655-3P	99.80	72.19	2909
HSA-MIR-4766-5P	99.75	69.23	2662
HSA-MIR-3714	99.71	70.74	2671
HSA-MIR-7154-5P	99.69	70.52	1900
HSA-MIR-646	99.68	67.84	1645
HSA-MIR-6887-3P	99.66	67.83	1778

Literature-anchored findings (GeneRIF, showing 15)

• Downregulated during osteoblastic differentiation of bone marrow stromal cells. Suggests role in skeletogenesis. (PMID:15325258)
• URB is expressed in human dermal papilla cells (PMID:15998583)
• In conclusion, the expression pattern of URB suggests its role in obesity and the results suggest that URB is secreted, at least in part, from adipocytes. (PMID:18178152)
• The CCDC80 protein has three P-DUDES structural domains. These domains have significant albeit remote sequence similarity to thioredoxin-like domains and are predicted to have an oxidoreductase function. (PMID:209648)
• Results reveal DRO1 as an AIB1-targeted tumor suppressor, providing a novel mechanism for AIB1-dependent inhibition of apoptosis. (PMID:21871888)
• Data suggest that CCDC80 expression is down-regulated in many thyroid carcinomas; loss of heterozygosity partially accounts for CCDC80 down-regulation in thyroid carcinoma; CCDC80 expression positively regulates expression of E-cadherin. (PMID:23666966)
• activation of PKGI with cGMP regulated SSG1 intracellular distribution. (PMID:23831687)
• Ccdc80 is a novel betacat-regulated gene in adrenocortical cells (PMID:25029241)
• Our finding of upregulated CCDC80 expression in the visceral adipose tissue of obese patients indicates that it may be a component of the obesity-altered secretome in this depot. Furthermore, the presence of CCDC80 protein in human serum and its association with systemic metabolic dysfunction suggests that it may be linked to metabolic changes in other organs. (PMID:28850155)
• The authors identified that CCDC80 has genetic and functional relevance to Intracranial Aneurysm pathogenesis in the French-Canadian population. (PMID:29531279)
• LINC01279 and MSC-AS1 were upregulated in endometriosis. LINC01279 may be associated with the pathogenesis of endometriosis. (PMID:30106115)
• Plasma asprosin, CCDC80 and ANGPTL4 levels are associated with metabolic and cardiovascular risk in patients with inflammatory bowel disease. (PMID:33676388)
• The expression of long non-coding RNA LINC01279 in gastric adenocarcinoma and its clinical significance. (PMID:34507839)
• Loss of DRO1/CCDC80 in the tumor microenvironment promotes carcinogenesis. (PMID:35422964)
• Silencing immune-infiltrating biomarker CCDC80 inhibits malignant characterization and tumor formation in gastric cancer. (PMID:38872096)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Ccdc80	ENSMUSG00000022665
rattus_norvegicus	Ccdc80	ENSRNOG00000002052

Protein

Protein identifiers

Coiled-coil domain-containing protein 80 — Q76M96 (reviewed: Q76M96)

Alternative names: Down-regulated by oncogenes protein 1, Up-regulated in BRS-3 deficient mouse homolog

All UniProt accessions (3): Q76M96, C9J8I6, H7C5K4

UniProt curated annotations — full annotation on UniProt →

Function. Promotes cell adhesion and matrix assembly.

Subunit / interactions. Binds to various extracellular matrix proteins.

Subcellular location. Secreted. Extracellular space. Extracellular matrix.

Tissue specificity. Expressed in dermal papilla and dermal fibroblasts (at protein level). Expressed in heart, thymus, placenta, pancreas, colon, epithelium, spleen and osteoblasts.

Post-translational modifications. Phosphorylated.

Induction. Down-regulated in cancer and after osteoblastic differentiation. Up-regulated by dihydrotestosterone (DHT).

Similarity. Belongs to the CCDC80 family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q76M96-1	1	yes
Q76M96-2	2
Q76M96-3	3

RefSeq proteins (2): NP_955805, NP_955806 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR025232	DUF4174	Domain

Pfam: PF13778

UniProt features (24 total): compositionally biased region 10, sequence conflict 4, region of interest 3, cross-link 2, splice variant 2, signal peptide 1, chain 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q76M96-F1	62.51	0.28

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 545, 548

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 213 (showing top): WAMUNYOKOLI_OVARIAN_CANCER_LMP_DN, CHIARADONNA_NEOPLASTIC_TRANSFORMATION_KRAS_DN, GOBP_POSITIVE_REGULATION_OF_CELL_ADHESION, SENESE_HDAC1_AND_HDAC2_TARGETS_DN, TERAMOTO_OPN_TARGETS_CLUSTER_6, PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_UP, KOYAMA_SEMA3B_TARGETS_UP, TGCTGAY_UNKNOWN, KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_DN, TCF11_01, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_DN, OCT1_07, GGGNNTTTCC_NFKB_Q6_01, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_5, ARGGGTTAA_UNKNOWN

GO Biological Process (3): response to bacterium (GO:0009617), positive regulation of cell-substrate adhesion (GO:0010811), extracellular matrix organization (GO:0030198)

GO Molecular Function (3): fibronectin binding (GO:0001968), heparin binding (GO:0008201), glycosaminoglycan binding (GO:0005539)

GO Cellular Component (5): basement membrane (GO:0005604), interstitial matrix (GO:0005614), extracellular region (GO:0005576), membrane (GO:0016020), extracellular matrix (GO:0031012)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
extracellular matrix	2
cellular anatomical structure	2
response to other organism	1
regulation of cell-substrate adhesion	1
cell-substrate adhesion	1
positive regulation of cell adhesion	1
extracellular structure organization	1
external encapsulating structure organization	1
protein binding	1
glycosaminoglycan binding	1
sulfur compound binding	1
carbohydrate derivative binding	1
external encapsulating structure	1

Protein interactions and networks

STRING

1658 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CCDC80	BRS3	P32247	917
CCDC80	CHI3L1	P30923	477
CCDC80	CCL19	Q99731	474
CCDC80	TRAM2	Q15035	457
CCDC80	ZNF628	Q5EBL2	447
CCDC80	OR10A3	P58181	446
CCDC80	ADRA2C	P18825	443
CCDC80	GDNF	P39905	442
CCDC80	IL18	Q14116	432
CCDC80	OXT	P01178	427
CCDC80	NTRK2	Q16620	424
CCDC80	SDC1	P18827	423
CCDC80	LRRC32	Q14392	414
CCDC80	SRPX	P78539	411
CCDC80	MMP12	P39900	403

IntAct

23 interactions, top by confidence:

A	B	Type	Score
MED21	MED19	psi-mi:“MI:0914”(association)	0.880
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
PPP2R3A	WTIP	psi-mi:“MI:0914”(association)	0.640
CSN2	CRYBB3	psi-mi:“MI:0914”(association)	0.530
ISX	MOCS3	psi-mi:“MI:0914”(association)	0.530
SDC1	ILVBL	psi-mi:“MI:0915”(physical association)	0.400
PCNA	CCDC80	psi-mi:“MI:0915”(physical association)	0.370
CCDC80	GCNT1	psi-mi:“MI:0915”(physical association)	0.370
CCDC80	TFAP2A	psi-mi:“MI:0915”(physical association)	0.370
CCDC80	TFAP2C	psi-mi:“MI:0915”(physical association)	0.370
DLST		psi-mi:“MI:0914”(association)	0.350
CUL4B	APBB1	psi-mi:“MI:0914”(association)	0.350
ARHGAP19	IFIT5	psi-mi:“MI:0914”(association)	0.350
PARP12	CASC3	psi-mi:“MI:0914”(association)	0.350
REXO4	ZNF316	psi-mi:“MI:0914”(association)	0.350
SATB2	CRYBB1	psi-mi:“MI:0914”(association)	0.350
THAP11	XPC	psi-mi:“MI:0914”(association)	0.350
GATA2	ILVBL	psi-mi:“MI:0914”(association)	0.350

BioGRID (10): CCDC80 (Affinity Capture-MS), CCDC80 (Affinity Capture-MS), CCDC80 (Affinity Capture-RNA), CCDC80 (Affinity Capture-MS), CCDC80 (Affinity Capture-MS), CCDC80 (Affinity Capture-MS), VCL (Cross-Linking-MS (XL-MS)), NPM1 (Cross-Linking-MS (XL-MS)), CCDC80 (Cross-Linking-MS (XL-MS)), CCDC80 (Affinity Capture-MS)

ESM2 similar proteins: A1XQX3, A1XQY0, A1XQY3, A6QLD2, D0PRN4, E9PUN2, O35181, O35464, O93279, O94933, O94991, P05067, P08592, P12023, P15379, P15943, P49415, P53601, P56975, P58401, P79307, Q06335, Q06481, Q27394, Q3UH99, Q3V1G4, Q58EG3, Q5IS80, Q5R3F8, Q60495, Q63376, Q68BL8, Q68FM6, Q6DR98, Q6QD51, Q6ZSJ9, Q76KF0, Q76M96, Q7TMB7, Q810B7

Diamond homologs: A0A1D5NSM8, B5DF94, O60687, P08607, P0C6B8, P42201, P78539, P98109, Q2VPA4, Q3SYW2, Q5EA25, Q63769, Q6GP28, Q6QD51, Q76M96, Q8R054, Q8R2G6, Q9R0M3, P04186, P16109, P98105, O08569, P0DTN2, P24083, P24084, P79138, Q01227, Q29RN8, Q4V9Z5, Q60736, Q6AX42, Q6UXD5, Q7TSY4, Q8AXP2, Q90X49, Q95LG1

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

150 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	125
Likely benign	13
Benign	4

Top pathogenic / likely-pathogenic (0)

SpliceAI

1252 predictions. Top by Δscore:

Variant	Effect	Δscore
3:112605759:GCTCC:G	acceptor_gain	1.0000
3:112605760:CTCC:C	acceptor_gain	1.0000
3:112605760:CTCCC:C	acceptor_gain	1.0000
3:112605761:TCC:T	acceptor_gain	1.0000
3:112605761:TCCCT:T	acceptor_gain	1.0000
3:112605762:CC:C	acceptor_gain	1.0000
3:112605762:CCC:C	acceptor_gain	1.0000
3:112605763:CC:C	acceptor_gain	1.0000
3:112605764:C:CC	acceptor_gain	1.0000
3:112605764:CTAG:C	acceptor_loss	1.0000
3:112605765:T:A	acceptor_loss	1.0000
3:112607202:C:CA	donor_gain	1.0000
3:112607203:C:A	donor_gain	1.0000
3:112607211:T:TA	donor_gain	1.0000
3:112607255:ACC:A	acceptor_loss	1.0000
3:112607256:CCTGA:C	acceptor_loss	1.0000
3:112616854:TATTG:T	acceptor_gain	1.0000
3:112616855:ATTG:A	acceptor_gain	1.0000
3:112616856:TTG:T	acceptor_gain	1.0000
3:112616857:TG:T	acceptor_gain	1.0000
3:112616859:C:CC	acceptor_gain	1.0000
3:112616859:C:G	acceptor_loss	1.0000
3:112616860:T:G	acceptor_loss	1.0000
3:112618962:CTGTA:C	donor_loss	1.0000
3:112618963:TGTAC:T	donor_loss	1.0000
3:112618964:GTACC:G	donor_loss	1.0000
3:112618965:TAC:T	donor_loss	1.0000
3:112618966:A:AC	donor_gain	1.0000
3:112618966:A:AT	donor_loss	1.0000
3:112618967:C:A	donor_loss	1.0000

AlphaMissense

6244 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:112605533:A:G	C913R	1.000
3:112605670:A:G	L867P	1.000
3:112605531:G:C	C913W	0.999
3:112605532:C:G	C913S	0.999
3:112605533:A:T	C913S	0.999
3:112605565:T:A	E902V	0.999
3:112605566:C:T	E902K	0.999
3:112605618:C:A	W884C	0.999
3:112605618:C:G	W884C	0.999
3:112605620:A:G	W884R	0.999
3:112605620:A:T	W884R	0.999
3:112605635:A:C	Y879D	0.999
3:112605641:A:G	S877P	0.999
3:112605642:T:A	K876N	0.999
3:112605642:T:G	K876N	0.999
3:112605657:T:A	K871N	0.999
3:112605657:T:G	K871N	0.999
3:112605658:T:A	K871I	0.999
3:112605664:A:T	V869D	0.999
3:112605667:A:G	L868P	0.999
3:112605709:C:G	R854P	0.999
3:112607229:A:G	L818P	0.999
3:112607235:A:G	L816P	0.999
3:112607251:G:T	R811S	0.999
3:112609985:G:C	C806W	0.999
3:112609986:C:G	C806S	0.999
3:112609986:C:T	C806Y	0.999
3:112609987:A:G	C806R	0.999
3:112609987:A:T	C806S	0.999
3:112610050:A:G	S785P	0.999

dbSNP variants (sampled 300 via entrez): RS1000050615 (3:112600973 T>C), RS1000164831 (3:112625510 C>A,G), RS1000165382 (3:112605038 G>A), RS1000252157 (3:112630387 T>C), RS1000339204 (3:112618502 G>T), RS1000474972 (3:112618287 G>A), RS1000528714 (3:112610556 C>T), RS1000578238 (3:112643013 A>C), RS1000768574 (3:112623777 G>A,C), RS1000919042 (3:112597736 C>T), RS1000962887 (3:112636683 T>C), RS1001017829 (3:112604317 A>G), RS1001031068 (3:112629869 C>G,T), RS1001101915 (3:112637001 G>A), RS1001253089 (3:112629057 C>T)

Disease associations

OMIM: gene MIM:608298 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST001709_11	Atopic dermatitis	2.000000e-19
GCST005576_2	Intracranial aneurysm	5.000000e-07
GCST007680_10	Triiodothyronine levels and thyroxine levels	4.000000e-06
GCST008839_509	Height	1.000000e-15

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0008392	triiodothyronine measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

49 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression, increases expression	4
trichostatin A	affects cotreatment, decreases expression	3
sodium arsenite	decreases expression, increases expression	3
Benzo(a)pyrene	decreases expression, increases expression, increases methylation	3
Tobacco Smoke Pollution	decreases expression	3
bisphenol A	decreases methylation, increases expression	2
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment, decreases expression	2
entinostat	decreases expression, affects cotreatment	2
(+)-JQ1 compound	decreases expression, increases expression	2
Air Pollutants	decreases expression, increases abundance	2
Estradiol	affects expression, affects cotreatment, increases expression	2
Cadmium Chloride	increases expression	2
aristolochic acid I	decreases expression	1
bisphenol F	increases expression	1
lead acetate	increases expression	1
sulforaphane	decreases expression	1
butyraldehyde	decreases expression	1
didecyldimethylammonium	decreases expression	1
nickel sulfate	decreases expression	1
cupric oxide	decreases expression	1
perfluorooctane sulfonic acid	decreases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, affects cotreatment	1
bisphenol B	increases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
bisphenol S	increases expression	1
jinfukang	affects cotreatment, decreases expression	1
NSC 689534	affects binding, increases expression	1
bisphenol AF	increases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_E0TT	Ubigene Hep G2 CCDC80 KO	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.